InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
SINTX Technologies is an OEM ceramics company that develops and commercializes sil...
SINTX Technologies is an OEM ceramics company t...
Vericel is a leader in advanced therapies for the sports medicine and severe burn ...
Vericel is a leader in advanced therapies for t...
After a good friend contracted HIV, I thought how could this happen? I was both sh...
After a good friend contracted HIV, I thought h...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Akari is a biopharmaceutical company focused on developing inhibitors of acute and...
Akari is a biopharmaceutical company focused on...
Join the National Investor Network and get the latest information with your interests in mind.